Jazz Pharmaceuticals plc (JAZZ) — ESG & Values Scores

Environment story

Jazz Pharmaceuticals discloses minimal environmental metrics in its 10-K. No Scope 1, 2, or 3 emissions data, renewable energy percentages, or net-zero targets are reported. The company mentions manufacturing facilities in Ireland, UK, and Italy, plus reliance on suppliers in China (WuXi for Ziihera), exposing operations to supply-chain carbon footprint risks. No evidence of decarbonization infrastructure investments or climate commitments. The 10-K focuses on drug pricing, regulatory, and supply-chain risks but contains no substantive environmental disclosure. Tariff and trade policy uncertainty may indirectly affect carbon footprint through supply-chain disruptions and inventory increases.

Criticisms on file

Supply-chain reliance on WuXi (China) for Ziihera manufacturing; exposure to BIOSECURE Act restrictions and potential U.S.-China trade sanctions affecting supply availability
Source: Jazz Pharmaceuticals 10-K, Risk Factors: Global trade issues and BIOSECURE Act
Tariff uncertainty and potential margin impact in 2026 due to pharmaceutical import tariffs; company increased U.S. inventory in anticipation
Source: Jazz Pharmaceuticals 10-K, MD&A and Risk Factors

Disclosed initiatives

Global supply chain manufacturing footprint

Operations in Ireland (Xywav, Xyrem), UK (Epidiolex/Epidyolex), Italy (defibrotide), and reliance on external suppliers including WuXi in China (Ziihera)

Social story

Jazz Pharmaceuticals does not disclose CEO-to-median-worker pay ratios, workforce diversity percentages, leadership diversity metrics, or turnover rates in the 10-K reviewed. No mention of union status, labor disputes, or formal diversity initiatives (DEI programs, supplier diversity, civil-rights audits, EEO-1 disclosures, HRC CEI scores). The company's focus on rare disease and highly specialized pharmaceutical workforce suggests a smaller, concentrated employee base, but detailed social metrics are absent. No documented union-suppression activities or strikes mentioned; however, absence of disclosure does not indicate strong social governance. Supply-chain ethics not addressed for manufacturing partners or API suppliers.

Criticisms on file

No disclosed workforce diversity, CEO pay ratio, or labor union data in 10-K; absence of formal DEI program disclosure
Source: Jazz Pharmaceuticals 10-K; comprehensive search for social metrics yielded no quantified disclosures

Disclosed initiatives

Patient support and access programs

Robust patient copay and savings programs for Xywav and other marketed products to facilitate access and affordability; patient counseling and monitoring through REMS

Mitigates patient financial barriers to therapy
Healthcare professional education

Educational initiatives targeting prescribers and patients on efficacy, safety (e.g., sodium reduction in Xywav vs. Xyrem), and clinical evidence

Supports informed prescribing and patient adoption

Governance story

Jazz Pharmaceuticals' 10-K does not disclose board independence percentage, share structure (single vs. dual-class), or annual lobbying expenditures. The company does not report PAC contributions or political spending breakdowns. Governance transparency is minimal. The 10-K extensively documents antitrust litigation—specifically, the Xyrem Antitrust Litigation (resolved as of October 2025), where Jazz was accused of using its REMS program to delay generic competition. Additional allegations exist regarding patent litigation settlement agreements and potential anticompetitive conduct under the CREATES Act and FTC scrutiny. No evidence of anti-climate lobbying or environmental deregulation advocacy. However, the volume and nature of regulatory scrutiny (REMS, CREATES, antitrust lawsuits, FTC investigations) indicates governance vulnerabilities and litigation exposure.

Criticisms on file

Xyrem Antitrust Litigation: Multiple lawsuits (June 2020–May 2022) alleging Jazz used REMS and patent settlement agreements to delay generic high-sodium oxybate approval; litigation centralized in Northern District of California; resolved entirely as of October 2025 (settlement terms not disclosed)
Source: Jazz Pharmaceuticals 10-K, Risk Factors and Note 13 (Legal Proceedings); MD&A
FTC/FDA/USPTO scrutiny of REMS programs: CREATES Act (2019) provides private right of action if Jazz denies competitor access to product samples; USPTO/FDA RFC (November 2022) questioned REMS patenting practices; FDA's 2015 letter expressed concern Jazz was aware REMS was blocking competition
Source: Jazz Pharmaceuticals 10-K, Risk Factors: REMS programs and anticompetitive practices
Ongoing patent litigation: Jazz filed suits against Zepzelca ANDA filers (September 2024); Xywav ANDA filers (Lupin, Teva, Granules, Tris Pharma); Epidiolex ANDA filers. Multiple tentative/final approvals of generics granted; Jazz granted extended exclusivity windows via settlements
Source: Jazz Pharmaceuticals 10-K, Risk Factors and Note 13; MD&A
Potential additional government investigations: Risk factor notes FTC, FDA, or other authorities could claim REMS misuse or anticompetitive conduct; possibility of additional lawsuits making similar allegations
Source: Jazz Pharmaceuticals 10-K, Risk Factors: Government investigations and REMS anticompetitive claims
REMS waiver and multiple REMS programs: FDA waived requirement for single shared REMS for Hikma AG and approved separate REMS for multiple high-sodium oxybate sponsors; creates operational complexity and potential liability for adverse outcomes attributed to other companies' REMS systems
Source: Jazz Pharmaceuticals 10-K, Risk Factors: Multiple REMS systems and liability risk

Disclosed initiatives

REMS compliance and FDA oversight

Jazz maintains and operates Xywav/Xyrem Risk Evaluation and Mitigation Strategy (REMS) with ETASU; FDA-approved modifications implemented in January 2024 in response to January 2023 FDA requests

Ensures regulatory alignment and patient safety monitoring
Patent litigation settlements with generic sponsors

Entered into settlements with 10 ANDA filers for Xyrem, 10 filers for Epidiolex (generic launches delayed to late 2030s), and multiple filers for Xywav and Zepzelca to manage competition timelines

Extends market exclusivity periods; exposed to antitrust litigation claims

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Jazz Pharmaceuticals plc. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Jazz Pharmaceuticals plc in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)